CFDA approved our IND application of Pirotinib Hydrochloride (KBP-5209)
2015-08-07 16:41:07 Author:admin

     CFDA approved our IND application of Pirotinib Hydrochloride (KBP-5209) today and more importantly granted us a full permission of clinical trials I-III! This unusual approval suggests not only a big leap in progress of our government regulatory agency, but also an ever-growing capabilities of our R&D.The project will be moved forward in US and China simotaniously after FIH is realized expectedly in coming October. This model of a China-centric internaltional multi-center clinical trial is a new innovation and will expect to impact pharma industry significantly. 

Email | Terms of Use | Contact us

2014版权?轩竹生物科技有限公司保留所有权利 鲁ICP备09030169号

国产对白